联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20170420 | --- | --- | --- | --- | --- | --- | |--------------------|--------------------------|----------------------------|-------------|------------------------------------------------------|----------------------------------------------------------------| | 投资者关系活动类别 | √特定对象调研 | | □分析师会议 | | | | | □媒体采访 □业绩说明会 | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | | □现场参观 □其他（投资者接待日活动） | | | 参与单位名称及人员 | | | | 东北证券 邹兰兰、王栋 中泰证券 康海涛 | | | | 大平基金 | 张翼翔 | | 浙商证券 邓胜、曹承安 | | ...

Group 1: Agricultural Business Insights - The cyclical nature of the pesticide industry has led to a decrease in overall demand for pesticide intermediates in 2016, but communication with clients indicates that business in 2017 is expected to improve significantly compared to 2016 [1] - Mergers and restructuring among upstream clients, such as DuPont and Dow's merger, are likely to reduce and optimize the supplier list, which could benefit the company as a preferred supplier due to its competitive advantages in customized services [1] - The company currently has no plans to expand into the pesticide or pharmaceutical formulation fields, despite recognizing significant growth potential in the custom services for intermediates and active ingredients [1] Group 2: Pharmaceutical Business Strategy - The global market for pharmaceuticals is large, and the company's strategy focuses on the production of advanced intermediates and active pharmaceutical ingredients, aligning with client expectations [2] - The company targets innovative pharmaceutical companies rather than generic drug firms, emphasizing the importance of innovation and reliability as key supplier characteristics [2] - Many clients have chosen the company as their preferred strategic partner, entrusting it with the production of their marketed products and involving it in their R&D efforts, ensuring stable future business development [2] Group 3: Operational Challenges and Market Dynamics - The Texas facility's production halt due to a safety incident has impacted the company's performance, but production is being restored in an orderly manner, with expectations to return to normal levels by the end of November [2] - Fluctuations in raw material prices can affect profit margins for the company's proprietary products; however, for the custom processing business, which charges processing fees, the impact is minimal due to many products being under patent protection [2] - The company has established three major divisions for functional chemicals, aiming to integrate existing resources and expand product offerings, balancing custom processing and proprietary product development [2]

Group 1: Investor Relations Activities - The investor relations activity was a targeted research event held on November 22, 2016, at the company's Shanghai office [1] - Participants included representatives from various funds and securities firms, indicating a diverse interest in the company's performance [1] Group 2: Agricultural Chemicals Business - The company's agricultural chemicals business primarily serves international clients, with domestic sales being relatively small [1] - Demand for agricultural intermediates is expected to improve in 2017, as customer inventory levels have bottomed out [1] - The cyclical nature of the agricultural industry and customer inventory adjustments have led to a weakened overall demand in 2016 [1] Group 3: Pharmaceutical Business Strategy - The pharmaceutical market is large, and the company aims to focus on the production of high-end intermediates and active pharmaceutical ingredients [2] - The company is targeting innovative pharmaceutical companies rather than generic drug firms [2] Group 4: Mergers and Acquisitions - The company is actively seeking quality acquisition targets, focusing on pharmaceutical intermediates and active pharmaceutical ingredients [2] - There is a noted gap in quality control systems between Chinese companies and international pharmaceutical giants, affecting trust and supplier relationships [2] - The establishment of a mergers and acquisitions department is seen as a key strategy for future growth [2] Group 5: Production Recovery and Capital Expenditure - The production at the Texas facility is being restored in an orderly manner, with full recovery expected by the end of November 2016 [2] - The company has made significant investments in infrastructure in recent years, with future capital expenditures expected to be lower as expansions will primarily involve building and upgrading facilities [2] Group 6: Impact of Industry Consolidation - The acquisition of Syngenta by ChemChina is not expected to rapidly change the supply chain, and the company is confident in maintaining its competitive position [3] - The merger of DuPont and Dow is anticipated to enhance the company's status as a preferred supplier in the agricultural sector [3]

Group 1: Company Strategy and Leadership - The company has been pursuing an international development strategy since 2015, with a significant acquisition in February 2017 of a UK-based advanced R&D and production custom processing company [1] - Andreas Winterfeldt was appointed as the new CEO due to his extensive experience in multinational corporations and strong leadership demonstrated during his tenure in the pharmaceutical division [1] Group 2: Environmental Considerations - Recent increases in environmental fees due to stricter national policies may impact future development, but the company prioritizes environmental governance and aims to enhance its core competitiveness in this area [2] - The company’s factories are located in chemical parks, and it is committed to maintaining high levels of environmental investment [2] Group 3: Acquisition Rationale - The target company has negative net assets and profits primarily due to high capital costs, but it possesses certain gross margins that could improve post-acquisition through integration with the company [2] - The acquisition of FINE ORGANICS is expected to create synergies, as it focuses on early product lifecycle stages, complementing the company’s strengths in later stages [2] Group 4: Market Position and Future Prospects - The acquisition will transition the company from a regional player to an international competitor, enhancing market reach and strategic partnerships [3] - Recent mergers among multinational companies in the pesticide sector may favor the company as a preferred supplier due to its competitive advantages in customized services [3] - The successful FDA certification of the Jiangkou factory signifies a high-quality cGMP system, which will attract more strategic partnerships and positively impact future business performance [3]

Group 1: Company Operations and Strategy - The production at Texas Lianhua has fully resumed since early December 2016, and it will not impact the business in 2017 [1] - The establishment of a subsidiary in Singapore is a key step in the company's internationalization strategy, aimed at accumulating operational experience for future expansions outside China [1] - The company is actively seeking high-quality acquisition targets, focusing on intermediates and raw materials [1] Group 2: Market Dynamics and Challenges - The quality control systems of Chinese pharmaceutical companies still lag behind those of European and American clients, leading to a trust gap with international pharmaceutical giants [1] - Currently, Chinese pharmaceutical intermediates are small in scale and often serve as supplementary suppliers, with prices being 20%-30% higher than foreign products [1] - The global demand for agricultural intermediates weakened in 2016 due to the cyclical nature of the agricultural industry and inventory adjustments by clients [2] Group 3: Future Outlook and Financial Considerations - International agricultural giants have completed their destocking phase and are entering a restocking phase, which is expected to boost global agricultural demand in the coming years [2] - The company has made significant investments in its bases, such as the Duqiao base, and future capital expenditures are expected to decrease, potentially allowing for an increase in dividend payouts [2]

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20170302 | --- | --- | --- | |-------------------------|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | √特定对象调研 | □分析师会议 | | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | | □现场参观 □其他（投资者接待日活动） | | 参与单位名称及人员 姓名 | 银河基金 中融信托 圆信永丰 银华基金 薄官辉 兴全基金 | 张瑞 招商基金 吴锡雄 曹翔 中国人寿 阳宜洋 张一苇 远策投资 谢利 国泰基金 金烨 朱璘 富国基金 燕云 | | 时间 | 2017 年 3 月 2 日 | | | 地点 ...

联化科技股份有限公司 2022 年第三季度报告 □是 否 证券代码：002250 证券简称：联化科技 公告编号：2022-046 联化科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|-------------------|------------------------|------------------|---------------- ...

联化科技股份有限公司 2022 年半年度报告全文 联化科技股份有限公司 2022 年半年度报告 二〇二二年八月 1 联化科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 | --- | |---------------------------------------------------------------------| | | | 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人 | | 管人员 ) 薛云轩声明：保证本半年度报告中财务报告的真实、准确、完整。 | | 所有董事均已出席了审议本报告的董事会会议。 | | 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公 | | 司对投资者的实质性承诺，敬请投资者注意投资风险。 | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | 2 联化科技股份有限公司 2022 年半年度报告全文 目录 | --- | |----------------- ...

联化科技股份有限公司 2022 年第一季度报告全文 1 证券代码：002250 证券简称：联化科技 公告编号：2022-019 联化科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 本报告期 上年同期 本报告期比上年同期增减 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|----------------- ...